Phase II study of neoadjuvant chemotherapy of TS-1, CDDP and Paclitaxel for resectable large type 3 or type 4 gastric cancer
Not Applicable
- Conditions
- Advanced gastric cancer
- Registration Number
- JPRN-UMIN000014332
- Lead Sponsor
- School of Medicine, Keio University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) with severe drug allergy 2) with highly lymph node metastases 3) with severe infection 4) with severe diarrhea 5) with severeintestinal paralysis or ileus 6) with interstitial pneumonia or pulmonary fibrosis with other active malignant disease 7) with active other malignancy 8) with severe diabetes 9 ) with severe heart disease 10) pregnant or nursing women or women who like be pregnant and willing to get pregnant
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 2-year overall survival
- Secondary Outcome Measures
Name Time Method